The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors
Autor: | Alejandro Balsa, Victoria Navarro-Compán, María Ángeles González, Borja Hernández-Breijo, Chamaida Plasencia-Rodríguez, Laura Nuño, Dora Pascual-Salcedo, Pilar Nozal, Irene Monjo, Ana Martínez-Feito |
---|---|
Rok vydání: | 2018 |
Předmět: |
Male
musculoskeletal diseases Drug medicine.medical_specialty media_common.quotation_subject Gastroenterology Arthritis Rheumatoid 03 medical and health sciences 0302 clinical medicine Rheumatology immune system diseases Internal medicine Adalimumab medicine Humans 030212 general & internal medicine skin and connective tissue diseases Aged media_common 030203 arthritis & rheumatology Tumor Necrosis Factor-alpha business.industry General Medicine Middle Aged medicine.disease Infliximab Logistic Models Methotrexate Treatment Outcome Antirheumatic Agents Concomitant Rheumatoid arthritis Drug Therapy Combination Female business Rheumatism medicine.drug |
Zdroj: | Clinical Rheumatology. 38:949-954 |
ISSN: | 1434-9949 0770-3198 |
Popis: | To investigate the effect of concomitant conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) with adalimumab or infliximab on maintaining serum drug and clinical outcomes after the first year of treatment in patients with rheumatoid arthritis (RA). Second, to assess the influence of methotrexate (MTX) dose on these outcomes. Ninety-two patients with RA starting infliximab (n = 67) or adalimumab (n = 25) tumor necrosis factor inhibitor (TNFi) with available drug levels and clinical improvement assessment (European League Against Rheumatism [EULAR] response) after 12 months were included. Patients were grouped according to concomitant csDMARD use: (i) TNFi monotherapy; (ii) TNFi+MTX; (iii) TNFi with csDMARDs other than MTX (TNFi+OD). Patients receiving MTX were also classified by dose as |
Databáze: | OpenAIRE |
Externí odkaz: |